Company: LENZ
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001815776-25-000071
Chunk: 346

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 8
Chunk 346
---
 basis. 

16

Assets and liabilities measured at fair value on a recurring basis are as follows (in thousands):Fair Value Measurements at Reporting DateTotalLevel 1Level 2Level 3At September 30, 2025:Cash equivalentsMoney market funds$24,735 $24,735 $— $— Total cash equivalents measured at fair value$24,735 $24,735 $— $— Marketable securitiesCorporate debt securities$57,463 $— $57,463 $— U.S. treasury securities49,772 49,772 — — Commercial paper46,733 — 46,733 — U.S. government agency securities12,967 — 12,967 — Asset-backed securities9,838 — 9,838 — Total marketable securities measured at fair value$176,773 $49,772 $127,001 $— At December 31, 2024:Cash equivalentsMoney market funds$17,693 $17,693 $— $— U.S. government securities999 — 999 — U.S. treasury securities997 997 — — Total cash equivalents measured at fair value$19,689 $18,690 $999 $— Marketable securitiesCommercial paper$58,823 $— $58,823 $— U.S. treasury securities46,309 46,309 — — Corporate debt securities43,669 — 43,669 — U.S. government agency securities40,071 — 40,071 — Total marketable securities measured at fair value$188,872 $46,309 $142,563 $— The following table presents the amortized cost and estimated fair market value of our cash equivalents and marketable securities as of the dates presented (in thousands):September 30, 2025Amortized CostGrossUnrealizedGainsGrossUnrealizedLossesEstimated FairValueCash equivalents:Money market funds$24,735 $— $— $24,735 Marketable securities:Corporate debt securities$57,402 $63 $(2)$57,463 U.S. treasury securities49,669 105 (2)49,772 Commercial paper46,712 25 (4)46